Table 4.
Novel agents investigated at the time of hypomethylating agent failure in MDS
AZA indicates azacitidine; DAC, Decitabine; HI, hematologic improvement; SD, Stable disease; mCR, marrow complete remission; CR, Complete remission; LDAC, low-dose cytarabine; and BSC, best supportive care.
